Category Archives: LDCs

Open Letter to Ambassadors (in India) of RCEP negotiating countries by Delhi Network of Positive People

Open Letter to Ambassadors of RCEP negotiating countries  Member countries Must Consider the Impact of RCEP on Access to Medicines in Developing Countries  Don’t trade our lives away! We are writing to you on behalf of the Delhi Network of … Continue reading

Posted in Data Exclusivity, FTA, Investor state dispute, IPR Enforcement, LDC transition period, Regional Comprehensive Economic Partnership, TRIPS plus, UN General Assembly HLM | Leave a comment

GSK expands graduated approach to patents and intellectual property to widen access to medicines in the world’s poorest countries

Source: GSK Press Release, 31 March 2016 Adopts approach to intellectual property reflecting a country’s economic maturity Will not file for patent protection in Least Developed and Low Income Countries Will seek to grant licences to generic manufacturers to supply … Continue reading

Posted in IP Rights, LDCs, Medicine Patent Pool, Patent, Uncategorized | Leave a comment

US Chamber of Commerce lauds USPTO for securing a time-bound LDC waiver for pharmaceutical products

Knowledge Ecology International; November 12, 2015. Nestled at the end Intellectual Property Watch’s (IP-Watch) brilliant reportage of a US Chamber of Commerce event – “Has the Sun Set on Multilateral Rulemaking on IP?” – is a quote by Patrick Kilbride (Executive … Continue reading

Posted in LDC transition period | Leave a comment

Joint NGO Statement on TRIPS Council Decision On Extension of the Transition Period Concerning Pharmaceutical Products

Knowledge Ecology International; November 6, 2015. On Friday, November 6, the WTO-TRIPS Council adopted a decision granting Least Developed Countries (LDCs) an exemption from patents and test data protection for pharmaceutical products for a duration of 17 years. A plethora of … Continue reading

Posted in LDC transition period, WTO | Leave a comment

17-year extension of pharma waiver – voices from NGOs

Last Thursday the US and the LDC Group reached agreement on a 17 year exemption from patents and test data protection for pharmaceutical Products. The agreement also includes waivers from mailbox and exclusive marketing rights obligations. The LDCs’ request for pharmaceutical … Continue reading

Posted in LDC transition period, Patents, US International Trade Commission (USITC) | Leave a comment

WTO Decision on Least Developed Country (LDC) Drug Patent Waiver

Knowledge Ecology International; November 3, 2015. Geneva — The World Trade Organization is poised to announce this Friday its approval of a limited 17-year extension of a 2001 waiver of obligations in the TRIPS Agreement, set to expire at the … Continue reading

Posted in August 30 decision, LDC transition period, LDCs, TRIPS | Leave a comment

Drugs row threatens health sector budget

Source: Daily Nation; October 6, 2015 Kenya may be forced to increase its future annual health budget, if global drug companies have their way in the simmering patents row surrounding the manufacture of medicines. They have pushed India, Kenya’s biggest … Continue reading

Posted in EU-India FTA, Indian Patent Law, Indian Patent Office, IP Rights, IPR policy, LDCs, Uncategorized | Leave a comment